Results of the phase 3 PERSIST-1 trial of pacritinib in myelofibrosis - European Medical Journal

Continue

Results of the phase 3 PERSIST-1 trial of pacritinib in myelofibrosis

Hematology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, Chair of Hematology at Mayo Clinic, Arizona, TX, discusses the trial design and results of the phase 3 PERSIST-1 trial of pacritinib, versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia-myelofibrosis.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given